A Chimeric Antigen Receptor specific for CD22 (ANTI-CD22 CAR) comprising: i) at least one extracellular domain comprising: - an antigen binding domain specific for CD22, optionally a leader sequence, - a hinge domain selected from FcγRIIIα, CD8alpha, IgG1, IgG4, and PD1, preferably from CD8 alpha, ii) a transmembrane domain, and iii) an intracellular signaling domain. wherein said antigen binding domain specific for CD22 comprises a single chain variable fragment (scfv) specific for CD22, said scfv comprising a heavy chain variable and light chain variable, comprising one of the following combination of sequences: (SEQ ID N° 71 and SEQ ID N° 72), (SEQ ID N° 73 and SEQ ID N° 74), (SEQ ID N° 75 and SEQ ID N° 76), (SEQ ID N° 77 and SEQ ID N° 78), (SEQ ID N° 79 and SEQ ID N° 80), (SEQ ID N° 81 and SEQ ID N° 82) (SEQ ID N° 83and SEQ ID N° 84), (SEQ ID N° 85 and SEQ ID N° 86), (SEQ ID N° 87 and SEQ ID N° 88) or (SEQ ID N° 89 and SEQ ID N° 90), more preferably a combination of sequences selected from (SEQ ID N° 77 and SEQ ID N° 78), (SEQ ID N° 83 and SEQ ID N° 84), (SEQ ID N° 87and SEQ ID N° 88), and (SEQ ID N° 89and SEQ ID N° 90) even more preferably the combination of sequences (SEQ ID N° 87 and SEQ ID N° 88), wherein said ANTI-CD22 CAR comprises at least one monoclonal antibody (mAb)-specific epitope(s) selected from: CPYSNPSLC, NSELLSLINDMPITNDQKKLMSNN, CQFDLSTRRLKC, CQYNLSSRALKC, CVWQRWQKSYVC, CVWQRWQKSYVC, SFVLNWYRMSPSNQTDKLAAFPEDR, SGTYLCGAISLAPKAQIKE, ELPTQGTFSNVSTNVSPAKPTTTA, ELPTQGTFSNVSTNVSPAKPTTTA, GQNDTSQTSSPS, preferably ELPTQGTFSNVSTNVSPAKPTTTA and/or CPYSNPSLC (SEQ ID N°91 and SEQ ID N°92). i) at least one extracellular domain comprising: - an antigen binding domain specific for CD22, optionally a leader sequence, - a hinge domain selected from FcγRIIIα, CD8alpha, IgG1, IgG4, and PD1, preferably from CD8 alpha, - an antigen binding domain specific for CD22, optionally a leader sequence, - a hinge domain selected from FcγRIIIα, CD8alpha, IgG1, IgG4, and PD1, preferably from CD8 alpha, ii) a transmembrane domain, and iii) an intracellular signaling domain. wherein said antigen binding domain specific for CD22 comprises a single chain variable fragment (scfv) specific for CD22, said scfv comprising a heavy chain variable and light chain variable, comprising one of the following combination of sequences: (SEQ ID N° 71 and SEQ ID N° 72), (SEQ ID N° 73 and SEQ ID N° 74), (SEQ ID N° 75 and SEQ ID N° 76), (SEQ ID N° 77 and SEQ ID N° 78), (SEQ ID N° 79 and SEQ ID N° 80), (SEQ ID N° 81 and SEQ ID N° 82) (SEQ ID N° 83and SEQ ID N° 84), (SEQ ID N° 85 and SEQ ID N° 86), (SEQ ID N° 87 and SEQ ID N° 88) or (SEQ ID N° 89 and SEQ ID N° 90), more preferably a combination of sequences selected from (SEQ ID N° 77 and SEQ ID N° 78), (SEQ ID N° 83 and SEQ ID N° 84), (SEQ ID N° 87and SEQ ID N° 88), and (SEQ ID N° 89and SEQ ID N° 90) even more preferably the combination of sequences (SEQ ID N° 87 and SEQ ID N° 88), wherein said ANTI-CD22 CAR comprises at least one monoclonal antibody (mAb)-specific epitope(s) selected from: CPYSNPSLC, NSELLSLINDMPITNDQKKLMSNN, CQFDLSTRRLKC, CQYNLSSRALKC, CVWQRWQKSYVC, CVWQRWQKSYVC, SFVLNWYRMSPSNQTDKLAAFPEDR, SGTYLCGAISLAPKAQIKE, ELPTQGTFSNVSTNVSPAKPTTTA, ELPTQGTFSNVSTNVSPAKPTTTA, GQNDTSQTSSPS, preferably ELPTQGTFSNVSTNVSPAKPTTTA and/or CPYSNPSLC (SEQ ID N°91 and SEQ ID N°92).